Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

BACKGROUND: Selecting patients for early clinical trials is a challenging process and clinicians lack sufficient tools to predict overall survival (OS). Circulating cell-free DNA (cfDNA) has recently been shown to be a promising prognostic biomarker. The aim of this study was to investigate whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Viller Tuxen, Ida, Barlebo Ahlborn, Lise, Mau-Soerensen, Morten, Staal Rohrberg, Kristoffer, Cilius Nielsen, Finn, Oestrup, Olga, Westmose Yde, Christina, Richter Vogelius, Ivan, Lassen, Ulrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738043/
https://www.ncbi.nlm.nih.gov/pubmed/31186525
http://dx.doi.org/10.1038/s41416-019-0491-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738043/
https://www.ncbi.nlm.nih.gov/pubmed/31186525
http://dx.doi.org/10.1038/s41416-019-0491-9

Ejemplares similares